Plasmodium ovale has long been considered a parasite that is predominantly found in Tropical Africa, most often in West Africa, and in some islands in the Western Pacific (1). Confirmed cases have occasionally been reported from other regions in which the parasite is endemic, except for the Americas (2, 3). Four factors have contributed to the perception that this species is relatively rare. The clinical course is short and comparatively mild (there are very few records of severity or mortality), the parasite burdens are generally low (peak parasitemias rarely exceed 25,000 parasites per μl of blood in naive individuals), the species is often misdiagnosed in areas where P. ovale is not known to be endemic, and finally, accurate diagnosis by microscopy examination, especially of thick smears, is difficult (2). The last two obstacles were circumvented by the introduction of sensitive molecular techniques (4). These provided the first indication that the prevalence and geographic range of P. ovale were likely to have been underestimated (5). Molecular-based detection also revealed a dimorphism in the P. ovale A-type small subunit rRNA (ssrRNA) genes (6, 7), which extended to other genes (8). Multilocus sequence analysis of isolates from diverse geographical origins culminated in the proposal that there were actually two species, P. ovale curtisi (classic type) and P. ovale wallikeri (variant type) (9). These two species are globally distributed and sympatric (6, 9–14).

In the context of a long-term goal to achieve malaria elimination, it becomes important to understand the epidemiology of P. ovale, a species which is more widespread than previously understood and which shares with P. vivax the formation of hypnozoites that cause relapses (15, 16). Recent observations suggest that the species might differ in their relapse patterns (17). Given the generally low parasite burdens, future investigations must incorporate molecular methods for sensitive detection and identification of the two species, as well as a means to discriminate between different strains using polymorphic markers. A number of protocols based on the ssrRNA genes (10, 12, 18) are suitable for identification but not for genotyping. Sequence and size variations were noted between the tryptophan-rich antigen genes (pocta and powtra) from P. ovale curtisi and P. ovale wallikeri (9). This was exploited in a nested PCR detection assay (11), where primers target sequences conserved between these two genes and the species are discriminated by the size of the amplified fragments (299 bp or 317 bp for pocta; 245 bp for powtra). The amplified fragment size variations result from differences in the number of repeated units, which suggests that a broader spectrum of size variants, possibly overlapping for P. ovale curtisi and P. ovale wallikeri, respectively, might occur. This would invalidate amplified fragment size difference as a means of distinguishing between P. ovale curtisi and P. ovale wallikeri.

When a set of P. ovale isolates collected from Thailand (n = 9; T series) and Vietnam (n = 2; V series) were tested using the species-conserved pocta oligonucleotides (11), a broader range of fragment sizes than that noted previously (11) was observed, with some overlap between the two species (Table 1). Consequently, we designed a new set of primers suitable for species-specific seminested PCR. The oligonucleotide primers were designed based on the pocta gene sequences available in GenBank (accession no. HM594182 to HM594183 for P. ovale curtisi, accession no. HM594180 to HM594181 for P. ovale wallikeri). For the primary reaction, a fragment of ca. 705 bp spanning the repeat region of pocta and powtra was amplified using oligonucleotides targeting regions conserved between the two species by using a new primer, PoTRA-F (5′-CATTTCACGTAGGACTCAAA-3′), which targets the 5′ end of the gene, and the previously published PoTRA rev3 (11). For the secondary amplification reaction, PoTRA-F was used in two separate reactions, but in this case with an oligonucleotide specific to each of the two species, either PocTRA-R (5′-TTTATGTATGGGTTTCTCTA-3′) or PowTRA-R (5′-TGTTGTTTGGTTTACTATCGTACTAG-3′) was used for P. ovale curtisi and P. ovale wallikeri, respectively (Fig. 1). The amplification conditions for the primary reaction were optimized by using genomic DNA isolated from P. ovale curtisi (T13)- or P. ovale wallikeri (T13-).
TABLE 1 Sizes of the sequenced *potra* fragments amplified using the different primer pairs

<table>
<thead>
<tr>
<th>Sample(s)</th>
<th><em>P. ovale</em> subspecies</th>
<th><em>Potra</em> fwd5′ + <em>Potra</em> rev5 (bp)</th>
<th><em>Potra</em> F′ + <em>Potra</em> R′ (bp)</th>
<th><em>Potra</em> F′ + <em>Power</em> R′ (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>POW1 or POW2</td>
<td><em>wallikeri</em></td>
<td>245</td>
<td>389</td>
<td>389</td>
</tr>
<tr>
<td>11 (Africa)</td>
<td><em>wallikeri</em></td>
<td>245</td>
<td>389</td>
<td>389</td>
</tr>
<tr>
<td>T7, T9, T11, T19</td>
<td><em>wallikeri</em></td>
<td>299</td>
<td>443</td>
<td>443</td>
</tr>
<tr>
<td>T22 (+ <em>P. vivax</em>)</td>
<td><em>wallikeri</em></td>
<td>299</td>
<td>443</td>
<td>443</td>
</tr>
<tr>
<td>T12 (+ <em>P. falciparum</em>)</td>
<td><em>wallikeri</em></td>
<td>299</td>
<td>443</td>
<td>443</td>
</tr>
<tr>
<td>VP, TVZ1</td>
<td><em>wallikeri</em></td>
<td>335</td>
<td>479</td>
<td>479</td>
</tr>
<tr>
<td>POCI</td>
<td><em>curtisi</em></td>
<td>299</td>
<td>443</td>
<td>443</td>
</tr>
<tr>
<td>VN, T14</td>
<td><em>curtisi</em></td>
<td>299</td>
<td>443</td>
<td>443</td>
</tr>
<tr>
<td>POC2</td>
<td><em>curtisi</em></td>
<td>317</td>
<td>461</td>
<td>461</td>
</tr>
<tr>
<td>T13</td>
<td><em>curtisi</em></td>
<td>353</td>
<td>497</td>
<td>497</td>
</tr>
</tbody>
</table>

* a POW1 and POW2 sequences were previously obtained (GenBank accession no. HM594180 and HM594181, respectively).  
* b GenBank accession no. for T19 is KF018430.  
* c GenBank accession no. for TVZ1 is KF018431.  
* d POCI and POC2 sequences were previously obtained (GenBank accession no. HM594182 and HM594183, respectively).  
* e GenBank accession no. for T14 is KF018433.  
* f GenBank accession no. for T13 is KF018432.

* POTRA* fragments amplified from *P. ovale wallikeri* (TVZ1)-infected blood samples (with respect to annealing temperature as well as Mg$^{2+}$ and oligonucleotide concentrations). The fragments obtained for each species were then cloned into the pCR 2.1 vector (Invitrogen, USA), and each plasmid was purified from the bacterial clones. These standard plasmids were used to optimize the conditions for the secondary amplification reactions (with respect to annealing temperature as well as Mg$^{2+}$ and oligonucleotide concentrations) and to derive the limit of detection of the seminested PCR protocol. The concentration of each standard plasmid stock solution was determined by using the optical density of the solution at 260 nm. The copy number of each standard plasmid per μl was calculated as the mass of the plasmid standard (g/μl) divided by the calculated mass of each molecule (number of bp × $600 g/6.027 × 10^{23}$). A serial dilution series, in which there were 1, 2, 5, 10, 10², 10³, 10⁴, or 10⁵ copies per μl, was then obtained, and 1 of each dilution was tested five times.

All reactions were carried out in a total volume of 20 μl in the presence of 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 75 or 125 μM for each deoxyribonucleotide triphosphate, and 0.4 units of *Taq* polymerase (Invitrogen, USA). The primary amplification was carried out at a final concentration of 2 mM MgCl₂ and 75 nM for each primer, with an annealing temperature of 56°C, whereas the secondary amplification was carried out using an annealing temperature of 60°C, with a final concentration of 3 mM for MgCl₂ and 125 nM for each primer. One microliter of template was used to initiate both the primary and secondary amplification reactions. The cycling parameters consisted of an initial denaturation step at 95°C for 5 min, annealing for 1 min, and then extension at 72°C for 1 min, followed by a denaturation step at 94°C for 1 min. After a given number of cycles (25 cycles for the primary amplification and 30 cycles for the secondary amplification), a final extension step at 72°C was carried out before storage of the product at 4°C. Ten microliters of the secondary reaction products was electrophoresed on a 2% agarose gel, and the bands were then visualized by UV transillumination, following staining with ethidium bromide.

The limit of detection, as based on the template with a known number of plasmid molecules, was five copies, for which all five duplicates gave a positive result. The specificity of the reaction was confirmed by using high concentrations of genomic DNA (equivalent to 10⁴ parasite genomes) from *P. falciparum*, *P. vivax*, *P. malariae*, or human DNA as templates alone (all reactions proved negative) or mixed with one or other of the standard plasmid templates that demonstrated that sensitivity was not affected. No detectable fragments could be amplified when plasmid DNA carrying the *potra* fragment from one *P. ovale* species was used as a template for the secondary amplification reaction, in which the primer pair specific for the *potra* of the other *P. ovale* species was used. The sensitivity and specificity of the protocol was then assessed by using genomic DNA purified from clinical blood samples containing *P. ovale curtisi* and *P. ovale wallikeri* that had been enumerated accurately (416 parasites/μl blood and 1,152 parasites/μl blood). These genomic DNAs were then serially diluted and assayed. The seminested protocol was able to consistently detect a parasitemia equivalent to 2 to 10 parasites/μl blood. The specificity and the consistency of the sensitivity were again confirmed by adding excess *P. falciparum*, *P. vivax*, *P. malariae*, or human genomic DNAs to the serially diluted DNA. Finally, genomic DNA templates from 30 patients infected with *P. falciparum* (n = 10), *P. vivax* (n = 10), or *P. malariae* (n = 10) were also tested and proved negative.

The seminested PCR protocol was then applied to DNA purified from 17 clinical blood samples: 7 samples infected with *P. ovale curtisi* (two of these were mixed infections with *P. falcipa-
genes could now serve as targets for molecular identification and as genetic markers suitable for a broad range of investigations of the epidemiology and biology of P. ovale curtisi and P. ovale wallikeri, similar to those carried out for P. falciparum and P. vivax (19–21).

Nucleotide sequence accession numbers. The potra gene sequences for samples T19, TVZ1, T13, and T14 were deposited in GenBank under accession numbers KF018430 to KF018433, respectively.

ACKNOWLEDGMENTS

This project was supported by Mahidol University and the Wellcome Trust (core support to the Wellcome Trust-Mahidol University-Oxford Tropical Medicine Research Programme), a Career Development Fellowship to M.I., and project grant WT091192MA awarded to C.J.S. C.J.S. is supported by Public Health England.

We thank Mary C. Oguike for providing samples, parasite DNA (samples 11 and 12), and primer sequences.

REFERENCES